EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische Studie

Lenvatinib Plus Pembrolizumab for Patients With Previously Treated Advanced Colorectal Cancer: Results From the Phase II LEAP-005 Study

Iván Victoria Ruiz, Nataliya V Uboha, Rahima Jamal, Fernando Contreras Mejía, Mónica Ahumada, Seock-Ah Im, Carlos Gomez-Roca, Ronnie Shapira-Frommer, Ruth Perets, Eduardo Yañez, Corina Dutcus, Chinyere E Okpara und 4 weitere

Clinical Colorectal Cancer · 2026-06 · 25 (2) · 225-238.e2

DOI: 10.1016/j.clcc.2026.01.003 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Clinical Colorectal Cancer, 2026-06. Verfasst von Iván Victoria Ruiz und 15 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology Department, Hospital Clinic i Provincial de Barcelona and Translational Genomics and Targeted Therapies in Solid Tumors, IDIBAPS, Ba…. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Colorectal Neoplasms, Quinolines, Phenylurea Compounds. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: MSD, Merck Sharp and Dohme United Kingdom, Eisai.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Current treatments for patients with previously treated metastatic colorectal cancer (CRC) have poor outcomes. LEAP-005 (ClinicalTrials.gov, NCT03797326) was a multicohort, open-label phase II study evaluating the efficacy and safety of lenvatinib plus pembrolizumab in participants with previously treated selected solid tumors. We report findings from the LEAP-005 CRC cohort. PATIENTS AND METHODS: Participants aged ≥ 18 years with advanced (metastatic and/or unresectable) CRC with 2 prior lines of systemic therapy were eligible for the CRC cohort of LEAP-005. Participants received oral lenvatinib (20 mg/day) plus intravenous pembrolizumab (200 mg Q3W) combination therapy (Arm 1) or lenvatinib (24 mg/day) monotherapy (Arm 2). Dual primary endpoints were objective response rate (ORR) per RECIST version 1.1 and safety. Secondary endpoints were duration of response (DOR), progression-free survival (PFS), and overall survival (OS). RESULTS: 135 participants were enrolled in the CRC cohort (Arm 1, n = 105; Arm 2, n = 35). In Arm 1, ORR was 14% (95% CI, 8-23), median PFS was 3.4 (95% CI, 2.1-4.1) months, and OS was 8.7 (95% CI, 7.0-10.0) months. In Arm 2, ORR was 7% (95% CI, 1-22), median PFS was 3.4 (95% CI, 2.1-4.2) months, and OS was 7.7 (95% CI, 5.6-14.8) months. Treatment-related AEs occurred in 96% of participants (grade 3/4, 63%) in Arm 1 and 97% (grade 3/4, 63%) in Arm 2. One participant in Arm 1 died due to treatment-related intestinal perforation. CONCLUSION: Lenvatinib plus pembrolizumab demonstrated antitumor activity in participants with advanced CRC with 2 prior lines of treatment. No new safety signals were identified.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedColorectal NeoplasmsQuinolinesPhenylurea CompoundsAntineoplastic Combined Chemotherapy ProtocolsHumansFemaleMaleMiddle AgedAgedAdultProgression-Free SurvivalAged, 80 and overResponse Evaluation Criteria in Solid Tumors

Stichwörter der Autor:innen

Gastrointestinal cancersImmune checkpoint inhibitorsMetastatic diseasePhase II clinical trialProtein kinase inhibitors

Substanzen

Antibodies, Monoclonal, HumanizedQuinolinesPhenylurea Compoundspembrolizumablenvatinib

Autor:innen und Institutionen

  • Medical Oncology Department, Hospital Clinic i Provincial de Barcelona and Translational Genomics and Targeted Therapies in Solid Tumors, IDIBAPS, Barcelona, Spain. Electronic address: ivictori@recerca.clinic.cat.
  • University of Wisconsin, Carbone Cancer Center, Madison, WI.
  • Centre de Recherche du CHUM, Centre Hospitalier de l'Université de Montréal, Montréal, Québec, Canada.
  • Instituto Nacional de Cancerología, Bogotá, Colombia.
  • Oncologa Medica, Departamento de Medicina Hospital Clínico Universidad de Chile and Departamento de Oncología Básico Clínico, Universidad de Chile, Santiago, Chile.
  • Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, South Korea.

Förderung

  • MSD
  • Merck Sharp and Dohme United Kingdom
  • Eisai
  • Eisai Canada
  • Merck

Zitieren

APA

Victoria Ruiz, I., Uboha, N. V., Jamal, R., Mejía, F. C., Ahumada, M., Im, S. A., Gomez-Roca, C., Shapira-Frommer, R., Perets, R., Yañez, E., Dutcus, C., Okpara, C. E., Ghori, R., Jin, F., Groisberg, R., & Castanon, E. (2026). Lenvatinib Plus Pembrolizumab for Patients With Previously Treated Advanced Colorectal Cancer: Results From the Phase II LEAP-005 Study. Clinical Colorectal Cancer, 25(2), 225-238.e2. https://doi.org/10.1016/j.clcc.2026.01.003

Vancouver

Victoria Ruiz I, Uboha NV, Jamal R, Mejía FC, Ahumada M, Im SA, et al. Lenvatinib Plus Pembrolizumab for Patients With Previously Treated Advanced Colorectal Cancer: Results From the Phase II LEAP-005 Study. Clinical Colorectal Cancer. 2026;25(2):225-238.e2. doi:10.1016/j.clcc.2026.01.003

BibTeX
@article{VictoriaRuiz2026,
  author = {Victoria Ruiz, Iván and Uboha, Nataliya V and Jamal, Rahima and Mejía, Fernando Contreras and Ahumada, Mónica and Im, Seock-Ah and Gomez-Roca, Carlos and Shapira-Frommer, Ronnie and Perets, Ruth and Yañez, Eduardo and Dutcus, Corina and Okpara, Chinyere E and Ghori, Razi and Jin, Fan and Groisberg, Roman and Castanon, Eduardo},
  title = {Lenvatinib Plus Pembrolizumab for Patients With Previously Treated Advanced Colorectal Cancer: Results From the Phase II LEAP-005 Study},
  journal = {Clinical Colorectal Cancer},
  year = {2026},
  volume = {25},
  number = {2},
  pages = {225--238.e2},
  doi = {10.1016/j.clcc.2026.01.003}
}
Kostenlos starten →